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Abstract
Background: Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery
with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance
an important issue. Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and
oral cancer cell lines. In this study, we determined clinical significance of GP96 in ORC by evaluation of GP96
expression and its association with disease prognosis in patients receiving radiotherapy
Methods: Total of 79 ORC patients (77 males, median age: 48 years old) receiving radical surgery and
postoperative radiotherapy between Oct 1999 and Dec 2004 were enrolled. Patients in pathological stages II, III
and IV were 16.5%, 16.5% and 67%, respectively. For each patient, a pair of carcinoma tissue and grossly adjacent
normal mucosa was obtained. GP96-expression was examined by western blot analysis, and the association with
clinicopathological status was determined.
Results: Three-year locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS)
and overall survival (OS) rates were 69%, 79%, 63% and 57%, respectively. We found that 55 patients (70%)
displayed GP96-overexpression in the tumor tissue, which correlated with a higher pN stage (p = 0.020) and tumor
depth (> 10 mm) (p = 0.045). Nodal extracapsular spreading (ECS) and GP96-overexpression predicted adverse LRC
(p = 0.049 and p = 0.008). When stratified by nodal ECS, the adverse impact of GP96 remained significant in three-
year LRC (p = 0.004). In multivariate analysis, GP96-overexpression was also an independent predictor of LRC, DSS
and OS (p = 0.018, p = 0.011 and p = 0.012).
Conclusion: GP96 may play roles in radioresistance which attributes to tumor invasiveness in oral cancer patients
receiving radiotherapy. GP96 may serve as a novel prognostic marker of radiotherapy. However, further
independent studies are required to validate our findings in a larger series.
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Background
Oral cavity cancers (ORC) are among the most common
cancers in the world [1]. Epidemiological studies have
shown strong associations between ORC and the use of
tobacco, alcohol and betel quid [2]. The standard treat-
ment for ORC is radical surgery [3]. Postoperative
radiotherapy (Postop-RT) with/without concurrent che-
motherapy is added to eliminate microscopic tumor
cells in high-risk patients. However, locoregional failure
remains a major problem if the tumor is radioresistant
[4-7].
Heat shock protein (Hsp) is a highly conserved mole-
cular chaperone protein that functions as biochemical
regulators of cell growth, apoptosis, and homeostasis. It
is up-regulated under stress conditions, such as starva-
t i o n ,h y p o x i a ,h e a t ,v i r u si n f e c t i o na n dn e o p l a s i a[ 8 , 9 ] .
Hsp GP96, also known as glucose-regulated protein 94
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any medium, provided the original work is properly cited.(GRP94), is a member of the Hsp 90 family [10]. It plays
an important role in regulating mitogenesis, cell cycle
and apoptosis [8,9,11]. In addition, GP96 has been
f o u n dt oi n d u c ep r o t e c t i v et umor-specific immunity
[11]. Recently, aberrant GP96-expression has been
observed in several cancers [12,13], suggesting a link
between neoplasms and GP96-expression. Our previous
work has shown that GP96 contributed to radioresis-
tance in nasopharyngeal carcinoma (NPC) and ORC cell
lines [14,15], indicating that this molecule may affect
the efficacy of radiotherapy. In this study, we investi-
gated the clinical significance of GP96 and the impact
on treatment outcome in ORC patients with Postop-RT.
Materials and methods
Patients and specimens
We obtained tissue bank specimens from ORC patients
visiting the Chang Gung Memorial Hospital-Linko
between Oct 1999 and Dec 2004. Samples were from 79
patients with newly diagnosed non-metastatic ORC
receiving radical surgery followed by Postop-RT. A
grossly normal sample of oral mucosal tissue as well as
a tumor specimen was collected. This study was
approved by the Institutional Review Broad of the
Human Investigation Committee in our institution.
Staging and Treatments
The pre-treatment workup included a chest X-ray, liver
ultrasound and bone scan to exclude distant metastases.
F18-FDG PET (18-fluoro, 2-fluoro-2-deoxy-D-glucose,
positron emission tomography) was incorporated after
Oct. 2003. Computed tomography (CT) or magnetic
resonance imaging (MRI) was used to determine tumor
burden. Radical surgery was defined as a wide excision
with a 1-2 cm safety margin with/without immediate
free-flap reconstruction. Mandibulectomy or maxillect-
omy were performed as dictated by tumor extension or
margin space. Ipsilateral elective neck dissection was
used for clinical N0 patients and radical neck dissection
for clinical N+ patients. Intraoperative frozen examina-
tions were performed to ensure adequate margins. The
definition of an adequate margin was a tumor-free mar-
gin of at least 5 mm according to final pathological
report. All tumor stage evaluations were revised accord-
ing to the 2002 AJCC pathological staging criteria.
Postop-RT was scheduled within 4-8 weeks of surgery
and was administered as 6 megavolt x-ray generated by
a linear accelerator. Conventional radiotherapy techni-
ques, 2-dimensional planning or 3-dimensional confor-
mal radiotherapy were used in early patients, while
intensity-modulated radiotherapy (IMRT) was incorpo-
rated after 2001. Conventional techniques consisted of
bilateral-opposing and lower-anterior neck portals. Neck
boosts by megavolt electron were used for sparing spinal
cord after 46 Gy. Doses of 1.8-2 Gy/fraction were given
in 5 fractions per week. Initial prophylactic doses of 46-
50 Gy were for all risk areas and a further boost of 60
Gy for the primary tumor bed and involved nodal areas.
Elevated doses of 66 Gy in combination with concurrent
chemotherapy were used in patients with positive mar-
gins, nodal extracapsular spreading (ECS) or pathologi-
cal multiple nodal metastasis. Concurrent chemotherapy
was administered with intravenous Cisplatin 50 mg/m2
and oral 5-FU analogue 1400 mg/m2 combined with
leucovorin 60 mg on a biweekly schedule during radio-
therapy. Patients were closely followed for at least three
years or until death. Patient status as of the last follow-
up was recorded at the last outpatient visit, telephone
interview or date of death.
Tissue processing, protein extraction and western blot
analysis
For each tissue, cellular proteins were extracted and the
level of GP96 protein was determined by western blot
method, similarly as previously described.
15 Briefly, total
of 20 μg tissues protein were separated by 8% SDS-poly-
acrylamide gel electrophoresis and transferred to a
nitrocellulose membrane. The membrane was hybridized
with an anti-GP96 antibody (NeoMarkers, Fremont, CA,
USA) and subsequently incubated with secondary anti-
bodies conjugated to horseradish peroxidase. The blots
were developed using Renaissance chemiluminescence
reagent (NEN Life Science Products, MA, USA) follow-
ing autoradiography. To determine the relative expres-
sion of GP96 in tumor tissue, the band density of each
tumor sample was compared with the normal oral
mucosa sample taken from the same patient after nor-
malization to an internal control (actin). GP96-overex-
pression was defined as a 1.5-fold increase in lesion
tissue as compared with the normal oral mucosa. The
level of GP96-expression and its associations with clini-
copathological parameters and treatment outcomes were
analyzed.
Statistical analysis
Time intervals were calculated from the end of RT to
the events of interest. Locoregional control (LRC) was
defined as freedom from relapse at the primary site or
neck, distant relapse for distant metastasis-free survival
(DMFS), and either one for disease-free survival (DFS).
Disease-specific survival (DSS) was defined as survival
until death from the disease or treatment-related toxici-
ties, and any other cause for overall survival (OS).
Relapse events were defined by imaging findings, clinical
or pathological examination. Commercial statistical soft-
ware (SPSS 13.0; SPSS, Chicago, IL) was used for data
analysis. Variables that might affect outcomes were eval-
uated using the chi-squared test, independent t-test or
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calculated by the Kaplan-Meier method with a log-rank
test for univariate analysis. A stepwise Cox-regression
model for multivariate analysis was used for further ana-
lysis of potentially significant variables.
Results
Patient characteristics and treatment outcome
Our study included 79 patients, and median age was 48
years old (range 30-75). The patient characteristics were
listed in Table 1. Pre-treatment imaging was performed
using MRI (n = 42, 53%), CT scan (n = 32, 41%) or
both (n = 5, 6%). Thirteen (16.5%) patients also had
F18-FDG PET scans to aid diagnosis. Primary tumor
site were buccal (n = 57, 72%) and majority of patients
were stage IV disease (67%). The detailed T-N distribu-
tion is shown in Table 2.
Radical surgery followed by Postop-RT was performed
in this cohort. The median nearest resection margin was
8 mm (range: 1-15), and no patients had positive mar-
gins. Neck dissection was ipsilateral (n = 67, 85%), bilat-
eral (n = 10, 13%), and none (n = 1). For Postop-RT,
elective neck irradiation was ipsilateral (n = 58, 73%)
and bilateral in remaining cases. The median time inter-
val between operation and radiotherapy was 5.5 weeks
( r a n g e :2 . 7 - 1 5 ) ,a n dam e d i a nd o s eo f6 6G y( r a n g e :5 6 -
68) in median of 7 weeks (rang: 5.8-16). Thirty-eight
(48%) patients received concurrent chemotherapy.
The median follow-up time was 4.3 years (range, 2.1-
8.0). At the end of the study, 39 patients remained alive
and 40 had died. Deaths were due to locoregional dis-
ease (n = 14), distant metastasis (n = 14), second pri-
mary malignancy (n = 3), intercurrent disease (n = 8)
and traffic accident (n = 1). Thirty-two patients suffered
from recurrent disease and the detailed failure pattern is
s h o w ni nF i g u r e1 .At o t a lo f2 0p a t i e n t s( 2 5 % )h a d
locoregional recurrence and 15 patients (19%) had dis-
tant metastasis. All locoregional failures were infield
recurrences except for two outfield neck recurrences.
GP96 is over-expressed in oral cavity cancers and predicts
poorer treatment outcome
Using the criterion of a 1.5-fold differential expression
in tumor tissue compared to the normal counterpart,
there were 9 out of 79 patients (11.4%) whose tumor
had GP96 under-expression (≤ 1.5-fold), 11 patients
(19.0%) equal expression (between 0.67- to 1.5-fold),
and 55 patients (69.6%) over-expression (≥ 1.5-fold, Fig-
ure 2). However, the treatment outcomes had no statis-
tical difference between under- and equal-expressed
patients. Therefore, we categorized GP96 under- and
equal-expression into the same group for analysis. The
associations between GP96 over-expression and clinico-
pathological factors are summarized in Table 1.
Table 1 Association between GP96 overexpression and
clinicopathological parameters
Total
patients
GP96 over-
expression
No Yes
No. % No. % No. % P
Gender 0.518*
Male 77 97.5 23 30 54 70
Female 2 2.5 1 50 1 50
Age (years) 0.573
≤ 48 44 51 11 27.5 29 72.5
> 4 8 3 9 4 9 1 33 32 66 7
Smoking 0.573*
No 14 18 4 29 10 71
Yes 65 82 20 31 45 69
Drinking 0.237
No 19 24 4 21 15 79
Yes 60 76 20 33 40 67
Betel-quid chewing 0.427*
No 14 18 5 36 9 64
Yes 65 82 19 29 46 71
Stage 0.349*
I-II 13 16.5 5 38.5 8 61.5
III-IV 66 83.5 19 29 47 71
T stage 0.390
T1-2 36 46 12 33 24 67
T3-4 43 54 12 28 31 72
Nodal stage 0.020
N0-1 44 56 18 41 26 59
N2 35 44 6 17 29 83
Nodal ECS 0.183
No 45 57 16 33 29 67
Yes 34 43 8 23.5 26 76.5
Differentiation 0.654
Well 24 30 9 37.5 15 62.5
Moderate 47 60 13 28 34 72
Poor 8 10 2 25 6 75
Depth (millimeters) 0.045
≤10 30 38 13 43 17 57
> 1 0 4 9 6 2 1 12 23 87 8
Skin invasion 0.641*
No 72 91 22 31 50 69
Yes 7 9 2 29 5 71
Bone invasion 0.402
No 56 71 18 32 38 68
Yes 23 29 6 26 17 74
Perineural invasion 0.424
No 53 67 15 28 38 72
Yes 24 30 8 33 16 67
Missing 2 3
Blood Vessel invasion
No 72 91 22 31 50 69 0.528*
Yes 5 6 1 20 4 80
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expression and nodal stage (p = 0.020) or tumor depth
(p = 0.045). Other associations were not observed.
The three-year overall LRC, DMFS, DFS, DSS and OS
were 69%, 78.6%, 57.5%, 63.3% and 56.6%, respectively.
The treatment prognosis evaluation by univariate analy-
sis and multivariate analysis were summarized in Table
3 and Table 4. In univariate analysis, patients with the
status of GP96-overexpression in tumors predicts poorer
treatment outcome on 3-year LRC (p = 0.008, Figure 3),
DMFS (p = 0.018), DFS (p = 0.001), DSS (p = 0.001)
and OS (p = 0.003). In multivariate analysis, GP96-over-
expression remained independent significance on LRC
(p = 0.018),D F S(p = 0.006),D S S(p = 0.011),O S(p =
0.012), and marginal effect on DMFS (p = 0.072).
Contribution of GP96-expression to LRC in N stage or
ECS-stratified populations
According to well-known pathological risk factors,
patients displaying positive margins, nodal ECS or pN2
stage disease are at high risk in terms of selection for
concurrent chemoradiotherapy [5-7,16]. Therefore, we
further examined the effect of GP96-expression in rela-
tion to these indicators. Because no case with positive
margins was available in this study, only pN2 stage dis-
ease and nodal ECS were used. In this study, 3-year
LRC for nodal ECS or pN2 were 54% and 62%, respec-
tively (Figure 4A-B). Further stratified by GP96-expres-
sion status, distinguishable four groups were observed.
In patients with nodal ECS, GP96-overexpression still
predicts poorer 3-year LRC 39% (vs.1 0 0 % )( F i g u r e4 C )
and also noted in patients with pN2 stage (54% vs.
100%) (Figure 4D). These results suggest that GP96
overexpression in tumor cells may be a significant pre-
dictor of poor prognosis for those patients receiving
radiotherapy.
Discussion
In this study, the treatment outcomes of ORC were
comparable to previously published data [5-7]. Our data
indicate that nodal ECS is a predictor of treatment out-
comes by univariate analysis (Table 3). This effect was
lost in the multivariate analysis of LRC, but it remained
significant for other outcome (Table 4). The impact on
treatment outcome of pN2 has only marginal effect.
This observation agrees with our retrospective data
Table 2 Distribution of pathological T and N stage
Pathological N stage
Pathological T stage N0 N1 N2 Total
T1 0 2 2 4 (5)
T2 13 6 13 32 (40.5)
T3 3 2 8 13 (16.5)
T4 12 6 12 30 (38)
Total 28 (36) 16 (20) 35 (44) 79 (100)
Values in parentheses are percentages
Figure 1 Treatment failure pattern.
Figure 2 GP96 is highly expressed in advanced oral cancer
tissues. Four pairs of normal (N) and tumor (T) tissues from oral
cancer patients were examined. Protein expression was determined
by western blot analysis. Actin protein expression served as an
internal control.
Table 1 Association between GP96 overexpression and
clinicopathological parameters (Continued)
Missing 2 3
Lymphatic vessel invasion 0.069*
No 65 82 22 34 43 66
Yes 12 15 1 8 11 92
Missing 2 3
Margin status (millimeters) 0.605*
≥ 5 66 83.5 20 30 46 70
< 5 13 16.5 4 31 9 69
* Fisher’s exact test
Abbreviations: ECS = extracapsular spreading
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LRC (%) p DMFS (%) p DFS (%) p DSS (%) p OS (%) p
Stage I-II
III-IV
81.8
66.4
0.245 84.6
77.5
0.548 69.2
55.1
0.282 76.9
60.4
0.208 76.9
54.2
0.033
T stage T1-2
T3-4
77.5
61.6
0.145 81.9
75.6
0.458 66.3
49.6
0.139 71.3
55.9
0.144 66.7
50.4
0.021
N stage N0-1
N2-3
74.1
62.2
0.196 87.5
66.8
0.023 66.7
45.8
0.024 75.8
46.6
0.007 72.3
40.0
0.002
Depth (millimeters) ≤10
>1 0
61.2
74.8
0.367 90.0
71.7
0.118 55.1
58.8
0.938 67.9
60.3
0.694 62.4
55.1
0.417
Differentiation Well
Moderate
Poor
72.0
67.1
75.0
0.818 86.6
82.5
37.5
0.003 66.0
56.6
37.5
0.264 70.2
64.1
37.5
0.203 66.7
56.8
37.5
0.580
Nodal ECS No
Yes
78.1
53.8
0.049 87.9
63.7
0.019 70.7
38.3
0.005 79.5
39.4
0.001 75.6
34.3
0.001
Skin invasion No
Yes
71.6
41.7
0.153 81.3
51.4
0.076 60.5
28.6
0.071 67.0
28.6
0.033 60.8
28.6
0.204
Bone invasion No
Yes
71.6
62.7
0.407 74.5
90.7
0.226 57.7
56.9
0.871 64.2
60.2
0.940 58.9
54.8
0.251
Perineural invasion No
Yes
68.1
71.9
0.717 81.3
69.2
0.295 58.6
51.9
0.349 67.8
50.0
0.170 62.0
45.8
0.318
Blood vessel invasion No
Yes
67.5
80.0
0.729 78.0
75.0
0.999 56.0
60.0
0.891 62.4
60.0
0.909 56.6
60.0
0.741
Lymphatic vessel invasion No
Yes
67.6
75.8
0.845 81.9
55.6
0.014 58.1
46.3
0.218 65.1
45.8
0.106 59.6
41.7
0.117
Margin status (millimeters) ≥ 5
<5
67.1
80.8
0.406 77.3
84.6
0.737 55.4
68.4
0.517 59.2
83.3
0.152 54.1
65.9
0.157
Concurrent chemotherapy No
Yes
70.8
67.8
0.613 89.3
66.0
0.014 65.2
48.9
0.071 72.6
52.4
0.506 70.6
44.3
0.022
GP96 overexpression No
Yes
90.2
58.7
0.008 95.8
69.5
0.018 86.5
44.7
0.001 95.7
49.0
0.001 87.5
44.9
0.003
Abbreviation: LRC = locoregional control; DMFS = distant metastasis-free survival; DFS = disease-free survival; DSS = disease-specific survival; OS = overall-survival;
ECS = extra-capsular spreading.
Table 4 Multivariate analysis of significant risk factors for
survival
P Hazard % 95 CI
LRC
GP96 over-expression 0.018 5.808 1.345-25.093
DMFS
GP96 over-expression 0.072 6.504 0.848-49.871
Skin invasion 0.020 4.973 1.289-19.190
Differentiation 0.015 3.975 1.309-12.065
Concurrent chemotherapy 0.052 3.276 0.992-10.821
DFS
GP96 over-expression 0.006 5.326 1.614-17.580
Nodal ECS 0.019 2.337 1.148-4.758
DSS
GP96 over-expression 0.011 6.532 1.530-27.890
Nodal ECS 0.014 2.698 1.225-5.942
Skin invasion 0.040 2.806 1.046-7.526
OS
GP96 over-expression 0.012 3.355 1.302-8.648
Nodal ECS 0.005 2.533 1.332-4.819
Abbreviation: LRC = locoregional control; DMFS = distant metastasis-free
survival; DFS = disease-free survival; DSS = disease-specific survival; OS =
overall-survival; ECS = extra-capsular spreading.
Figure 3 GP96-overexpression is a poorer prognostic factor on
locoregional control (LRC), as shown by the survival curves
calculated by the Kaplan-Meier method. GP96(+): GP96
overexpression, as the protein level is 1.5-fold higher in the tumor
tissue compared to the normal counterpart; GP96(-): GP96 non-
overexpression, as the protein level is comparable or lower (≤ 1.5-
fold) compared to the normal counterpart.
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come this negative effect, and considering of GP96-
expression is another important issue.
GP96, a 94-100 kDa Ca
2+-binding protein, is the most
abundant protein in the endoplasmic reticulum (ER). It
functions as a chaperone in ER, regulates mitogenesis,
apoptosis, and antigenic-presenting immune response
[8-11]. Up-regulation of GP96-expression has been
reported under stress conditions, including starvation,
hypoxia, heat, viral infection and neoplasia [8,9]. In the
presence of stress, the final fate of cells may depend on
their ability to resist stress. GP96 regulates cell fate by
maintaining the intracellular Ca
2+ balance between the
cytosol, ER and mitochondria. In this study, we exam-
ined GP96-expression in advanced ORC patients and
found that GP96 is overexpressed in 70% of patients,
which is consistent with previous findings indicating
that GP96 is overexpressed in several human neoplasms
[12,13,17]. It indicates that GP96 plays an important
role in cancer development and continuous expression
required for regulation and stabilizing tumor growth
[13]. We also found that GP96-expression was corre-
lated with tumor depth and N stage (Table 1). It is con-
sistent with reports suggesting associations between
elevated GP96-expression and tumor advanced stage or
invasive ability. In addition, we found that GP96-overex-
pression was a strong independent prognostic factor for
LRC, DFS, DSS and OS, although a marginal effect on
DMFS (Table 3). It is consistent with a previous report
indicating that GP96-expression serves as a poor prog-
nostic factor in gastric carcinoma [13].
As mentioned above, GP96-expression was a strong
predictor of LRC (p=0 . 0 0 8 , Table 3, Figure 3) and
was the only independent predictor in the multivariate
(A) (B)
(C) (D)
Figure 4 Contribution of GP96-expression on locoregional control (LRC) in nodal ECS (A) or pN2 (B) stage-stratified patients, and
provides additional information when stratified by risk of ECS (C) or N stage (D). All the survival curves were calculated by the Kaplan-
Meier method. ECS(+): positive for nodal ECS; ECS(-): negative for nodal ECS; N0-1: N0-1 stage; N2: N2 stage; GP96(+): GP96 overexpression, as
the protein level is 1.5-fold higher in the tumor tissue compared to the normal counterpart; GP96(-): GP96 non-overexpression, as the protein
level is comparable or lower (≤ 1.5-fold) 1.5-fold) compared to the normal counterpart.
Lin et al. Radiation Oncology 2011, 6:136
http://www.ro-journal.com/content/6/1/136
Page 6 of 8models (Table 4). We therefore hypothesize that GP96-
expression is strongly associated with tumor radioresis-
tance. Based on these observations, we further analyzed
the effect of GP96-expression using stratification by
well-established pathological risk factors such as nodal
ECS or pN2 stage; the adverse effect of GP96-expres-
sion was still distinguishable (Figure 4C-D). We
observed GP96-overexpression makes it poorer on
LRC in patients with nodal ECS or pN2 stage, suggest-
ing that GP96 may exhibit tumor radioresistance.
Interestingly, in non-GP96-overexpression group, if
patients with nodal ECS or pN2, which were high-risk
patients selected for concurrent chemotherapy, it has
inversely better 3-year LRC than low-risk patients who
received Postop-RT alone (Figure 4C-D). This might
be due to concurrent chemotherapy may effectively
enhance tumor cell-killing in normal GP96-expression
group.
In this study, our observations were consistent with
previous reports that GP96-overexpression reduced
radiosensitivity in cervical cancer and NPC cell lines
[14,18]. In addition, it supports the clinical evidence
comparable with our previous work on ORC cell lines:
increasing of GP96-expression was observed in radiore-
sistant sublines, and GP96-knockdown enhanced radio-
sensitivity via increasing G2/M arrest and reactive
oxygen species levels [15]. Therefore, GP96 may play
roles in radioresistance whicha t t r i b u t e st ot u m o ri n v a -
siveness in oral cancer patients receiving radiotherapy.
GP96 may serve as a novel prognostic marker of radio-
therapy. However, further independent studies are
required to validate our findings in a larger series.
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